A recently completed Phase Ib clinical trial of a new drug to treat inflammatory bowel disease (IBD) indicates that treatment may be possible with just a single daily dose. The drug, NV-52, is a novel compound being developed by Australian pharmaceutical company Novogen Limited (ASX: NRT) (NASDAQ: NVGN), as an oral agent for the maintenance of remission in IBD.
